Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.35 |
| ▸ | F11 | P03951 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17832297 | 0.90 | SLC9A1 (0.36) | SLC9A1F11NOS3NOS1NOS2 | |
| SCHEMBL24427493 | 0.76 | NOS3 (0.32) | NOS3NOS1NOS2PIM1PIM2 | |
| SCHEMBL24726064 | 0.70 | TLR9 (0.35) | NOS3NOS1NOS2GAA | |
| SCHEMBL17832296 | 0.70 | NOS3 (0.34) | NOS3NOS1NOS2PIM1PIM2 | |
| SCHEMBL24427823 | 0.68 | PIM2 (0.39) | F11NOS3NOS1NOS2PIM1 | |
| SCHEMBL24427895 | 0.67 | MEN1 (0.50) | GAA | |
| SCHEMBL24726301 | 0.67 | PIM1 (0.31) | PIM1PIM2PIM3 | |
| SCHEMBL24427896 | 0.65 | PIK3CD (0.43) | NOS3NOS2 | |
| SCHEMBL91461 | 0.64 | — | — | |
| SCHEMBL18319850 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | SLC9A1 562/4885F11 3/4885NOS3 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.